{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:00:05Z","timestamp":1780898405871,"version":"3.54.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PARP(Poly(ADP-ribose) polymerase) inhibitors are established as effective treatment for ovarian cancer; however, there have been no systematic studies of PARP inhibitor use in older patients with ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted at Peking University People\u2019s Hospital. Archival data from patients with advanced age (\u2265 65 years) with ovarian cancer between March 2018 and September 2023, who received olaparib or niraparib as maintenance therapy following either first-line platinum-based chemotherapy or platinum-sensitive recurrence (PSR) chemotherapy and achieved complete (CR) or partial response (PR). The two clinical scenarios (first-line maintenance and PSR maintenance) were analyzed separately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 56 included patients, 20 (35.7%) and 34 (60.7%) received olaparib and niraparib, respectively, while 2 (3.6%) switched from olaparib to niraparib due to intolerance. The mean age was 70.14 \u00b1 4.63 years. Median progression-free survival (mPFS) was 24 months in 35 (62.5%) patients receiving PARP inhibitors as first-line maintenance therapy(1L-group). In the 1L group, CA125 level, whether CR was reached,\n                      <jats:italic>BRCA<\/jats:italic>\n                      mutation status, and R0 at initial surgery before PARP inhibitor therapy were associated with PFS in univariate analysis, and the latter three factors were independently associated with PFS on multivariate analysis. In the PSR group, among patients with PSR \u226512 months (n=13), mPFS was not reached; among those with PSR 6\u201312 months (n=7), mPFS was 9.6 months. Anemia (22.7%) was the most frequent grade 3\u20134 adverse event in the olaparib group, whereas thrombocytopenia (11.1%) was more common in the niraparib group. Both groups of patients experienced dose reduction, interruption, and discontinuation within the first 6 months. Niraparib had a lower termination rate than olaparib, and long-term PARP inhibitor use was generally well-tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PARP inhibitor (olaparib and niraparib) maintenance therapy yields favorable clinical outcomes for elderly ovarian cancer patients. Three clinical factors, attainment R0(no residual disease) after initial surgery, BRCA mutation, and CA-125 \u226410 U\/mL before PARP inhibitor treatment, were predictive of longer PFS in elderly ovarian cancer patients undergoing first-line maintenance therapy with PARP inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1737880","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:37:09Z","timestamp":1780897029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingjing","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Department of Obstetrics and Gynecology, Handan Central Hospital","place":["Handan, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a Phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gocm-2025-000277","article-title":"New frontiers in the management of recurrent epithelial ovarian cancer: a comprehensive review","volume":"5","author":"De Tommasi","year":"2025","journal-title":"Gynecol Obstet Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-018-1083-x","article-title":"Avoidable waste of research related to outcome planning and reporting in clinical trials","volume":"16","author":"Yordanov","year":"2018","journal-title":"BMC Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30677-2","article-title":"Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of disease study","volume":"396","author":"Vollset","year":"2020","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100168","article-title":"A scoping review of national policies for healthy ageing in Mainland China from 2016 to 2020","volume":"12","author":"Ye","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(86)90623-x","article-title":"Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data","volume":"154","author":"Yancik","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-6-42","article-title":"Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium","volume":"6","author":"Trillsch","year":"2013","journal-title":"J Ovarian Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ijgc.2025.102017","article-title":"Advanced epithelial ovarian cancer in older patients","volume":"35","author":"Cullimore","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12672-025-04201-8","article-title":"Clinical characteristics, treatment status and prognosis analysis of elderly patients with ovarian cancer: a real world clinical study","volume":"17","author":"Wang","year":"2025","journal-title":"Discov Oncol"},{"key":"B18","unstructured":"NCCN clinical practice guidelines in oncology: older adult oncology. Version 1.2025\n          \n          2025"},{"key":"B19","article-title":"Chinese expert consensus on standardized surgical treatment of elderly ovarian cancer (2024 edition)","volume":"23","author":"Zhang","year":"2024","journal-title":"Chin J Multiple Organ Dis Elderly"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors ovarian cancer. Gynecologic cancer intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.09.008","article-title":"Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers","volume":"155","author":"Labidi-Galy","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1\u20132 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7373","article-title":"Pretreatment CA-125 and risk of relapse in advanced ovarian cancer","volume":"24","author":"Markman","year":"2006","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12885-020-6693-y","article-title":"Mutation landscape of germline and somatic BRCA1\/2 in patients with high-grade serous ovarian cancer","volume":"20","author":"Eoh","year":"2020","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2023.03.035","article-title":"Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis","volume":"187","author":"Peters","year":"2023","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34706","article-title":"Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"129","author":"Mirza","year":"2023","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03609-y","article-title":"First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature","volume":"27","author":"Masvidal Hernandez","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/go-25-00309","article-title":"Geriatric assessment: ASCO global guideline","volume":"11","author":"Bergerot","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdu210","article-title":"Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations","volume":"26","author":"Decoster","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1737880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:37:12Z","timestamp":1780897032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1737880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1737880"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1737880","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1737880"}}